Laboratoire de Pharmacologie-Toxicologie, Pharmacovigilance & CEIPA, CHRU de Nancy Brabois, Bâtiment de Biologie Médicale et de Biopathologie, Vandœuvre-lès-Nancy, France.
Service de Dermatologie, CHRU DE NANCY Brabois, Bâtiment des Spécialités Médicales, Vandœuvre-lès-Nancy, France.
Fundam Clin Pharmacol. 2023 Jun;37(3):673-679. doi: 10.1111/fcp.12866. Epub 2023 Jan 11.
Radiation recall reactions are inflammatory reactions confined to previously irradiated tissues, often of drug-induced etiology, particularly with anticancer therapies. Other drugs, in particular COVID-19 vaccines, may also be involved. To describe radiation recall reactions under non-anticancer drugs more precisely, we extracted the cases of radiation recall reactions associated with non-anticancer drugs from WHO pharmacovigilance database VigiBase®. We performed two analyses from this extraction: a global analysis and an analysis focusing on vaccination-related issues. We extracted 120 cases corresponding to 269 drugs, of which 130 were non-anticancer (22 vaccines). Among the non-anticancer drugs, tozinameran was the most reported treatment (4.46% of cases), followed by levofloxacin (2.97%) and folinic acid (2.60%), dexamethasone (2.23), and ChAdOx1 nCoV-19 vaccine and prednisone (1.86% each). Among vaccines, tozinameran (54.55% of cases) was the most reported, followed by ChAdOx1 nCoV-19 (22.73%), HPV and inactivated influenza vaccine (9.09% each), and elasomeran (4.55%). Our study first describes the occurrence of radiation recall reactions during non-anticancer treatment. It also highlights a potential safety signal with COVID-19 vaccines.
放射回忆反应是局限于先前照射组织的炎症反应,通常与药物有关,特别是与抗癌治疗有关。其他药物,特别是 COVID-19 疫苗,也可能参与其中。为了更准确地描述非抗癌药物下的放射回忆反应,我们从世界卫生组织药物警戒数据库 VigiBase®中提取了与非抗癌药物相关的放射回忆反应病例。我们从该提取中进行了两项分析:全球分析和关注疫苗相关问题的分析。我们提取了 120 例与 269 种药物相关的病例,其中 130 例是非抗癌药物(22 种疫苗)。在非抗癌药物中,托珠单抗是报告最多的治疗药物(占病例的 4.46%),其次是左氧氟沙星(2.97%)和亚叶酸(2.60%)、地塞米松(2.23%)、ChAdOx1 nCoV-19 疫苗和泼尼松(各占 1.86%)。在疫苗中,托珠单抗(占病例的 54.55%)报告最多,其次是 ChAdOx1 nCoV-19(22.73%)、HPV 和灭活流感疫苗(各占 9.09%),以及 elasomeran(占 4.55%)。我们的研究首次描述了非抗癌治疗期间放射回忆反应的发生情况。它还强调了 COVID-19 疫苗的潜在安全信号。